Clinical trials: Metastases, Neoplasm
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic…
- Trial name
- NCT01393730
- Testing
- Abiraterone acetate, Dutasteride, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mary-Ellen Taplin, MD
Spinal Metastases, Vertebral Metastases
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma
- Trial name
- NCT01347307
- Testing
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mercy Research
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Metastatic Cancer, Sarcoma
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00066365
- Testing
- sargramostim, conventional surgery
- Where
- 93 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Children's Oncology Group
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02097225
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Onalespib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal and Gynecologic Malignancies
Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Adult patients evaluated at Lahey Clinic with known or suspected gastrointestinal or gynecologic malignancies and with an indication for diagnostic laparoscopy will be offered participation in the study.
- Trial name
- NCT01944930
- Testing
- Laparoscopic narrow band imaging, Standard white-light laparoscopy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Lahey Clinic
Metastatic Cancer
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in…
- Trial name
- NCT02843165
- Testing
- Checkpoint blockade immunotherapy, Checkpoint blockade immunotherapy plus SBRT
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of California, San Diego
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial is studying the side effects and how well giving tipifarnib together with etoposide works in treating older patients with newly diagnosed, previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00602771
- Testing
- tipifarnib, etoposide
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic or Unresectable Cutaneous Melanoma
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC)…
- Trial name
- NCT01763164
- Testing
- MEK162, Dacarbazine
- Where
- 229 sites in United States, Argentina and 25 more
- Volunteers
- 402 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- GRABM-L (NCT01497665)
- Testing
- GRN1005
- Where
- 10 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Angiochem Inc
Metastatic Non-squamous Non Small Cell Lung Cancer
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
This is an efficacy and safety study of cosibelimab (CK-301) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic non-squamous non-small cell…
- Trial name
- CONTERNO (NCT04786964)
- Testing
- Cosibelimab, Cisplatin, Carboplatin
- Where
- 22 sites in Brazil, Georgia and 6 more
- Volunteers
- 25 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
- Trial name
- NCT00696696
- Testing
- Gemcitabine, Erlotinib, Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- NYU Langone Health
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been…
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Trial name
- NCT01514188
- Testing
- INNO-206, Doxorubicin
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 126 people
- Sponsor
- ImmunityBio, Inc.
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.